| Target Price | £47.48 | 
| Price | £43.85 | 
| Potential | 
             
      
            
    
      
    
  8.28%
     
      
        
          
          register free of charge 
        
   | 
      
| Number of Estimates | 17 | 
| 
        17 Analysts have issued a price target 3i 2026 .
        The average 3i target price is £47.48.
        This is    
       
    
      
    
  8.28%
     
      
        
          
          register free of charge 
        
  
                £54.60 
    
      
    
  24.52%
     
      
        
          
          register free of charge 
        
  
                £36.61 
    
      
    
  16.51%
     
      
        
          
          register free of charge 
        
   | 
    |
| A rating was issued by 22 analysts: 18 Analysts recommend 3i to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| 
        Analyst Estimates: Analysts believe that the 3i stock has an average upside potential 2026 of    
       
    
      
    
  8.28%
     
      
        
          
          register free of charge 
        
   | 
    
| Mar '25 | 
          2026 Estimates  | 
      |
|---|---|---|
| Revenue Billion £ | 5.16 | 6.89 | 
| 28.52% | 33.58% | |
| EBITDA Margin | 97.09% | 75.54% | 
| 1.76% | 22.20% | |
| Net Margin | 97.73% | 87.46% | 
| 2.19% | 10.51% | 
12 Analysts have issued a sales forecast 3i 2026 . The average 3i sales estimate is
This results in the following potential growth metrics:
13 3i Analysts have issued a net profit forecast 2026. The average 3i net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '25 | 
          2026 Estimates  | 
      |
|---|---|---|
| Earnings Per Share £ | 5.20 | 6.19 | 
| 30.98% | 19.04% | |
| P/E | 7.11 | |
| EV/Sales | 6.48 | 
13 Analysts have issued a 3i forecast for earnings per share. The average 3i EPS is
This results in the following potential growth metrics and future valuations:
| Analyst | Rating | Action | Date | 
|---|---|---|---|
| Citigroup | 
             Locked 
            ➜ 
            Locked 
           | 
          Locked | Oct 30 2025 | 
| Deutsche | 
             Locked 
            ➜ 
            Locked 
           | 
          Locked | Sep 25 2025 | 
| JP Morgan Cazenove | 
             Locked 
            ➜ 
            Locked 
           | 
          Locked | Jul 25 2025 | 
| Citigroup | 
             Locked 
            ➜ 
            Locked 
           | 
          Locked | Apr 15 2025 | 
| JP Morgan Cazenove | 
             Locked 
            ➜ 
            Locked 
           | 
          Locked | Jan 07 2025 | 
| Analyst Rating | Date | 
|---|---|
| 
          
            Locked
          
           
            Citigroup:
             
        Locked 
              ➜ 
              Locked 
             | 
        Oct 30 2025 | 
| 
          
            Locked
          
           
            Deutsche:
             
        Locked 
              ➜ 
              Locked 
             | 
        Sep 25 2025 | 
| 
          
            Locked
          
           
            JP Morgan Cazenove:
             
        Locked 
              ➜ 
              Locked 
             | 
        Jul 25 2025 | 
| 
          
            Locked
          
           
            Citigroup:
             
        Locked 
              ➜ 
              Locked 
             | 
        Apr 15 2025 | 
| 
          
            Locked
          
           
            JP Morgan Cazenove:
             
        Locked 
              ➜ 
              Locked 
             | 
        Jan 07 2025 | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


